Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CareDx Inc(CDNA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CDNA
09/17/2026: CDNA (4-star) is a STRONG-BUY. BUY for 105 days. Simulated Profits (154.96%). Updated daily EoD!
CareDx is a specialized biotechnology company focused on providing non-invasive molecular diagnostic testing and digital software for transplant patients. Its primary strength lies in its integrated platform, which combines blood-based tests like AlloSure with software for transplant center management. The investment story centers on capturing long-term growth by improving clinical outcomes through better monitoring. However, the company faces significant risks from intense competition, regulatory scrutiny, and dependence on favorable insurance reimbursement. CareDx may suit investors with a higher risk tolerance who are willing to navigate sector-specific volatility while monitoring for consistent revenue growth and profitability improvements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company operates in a niche growth market but faces significant regulatory and competitive headwinds. |
| Momentum investor | Weak fit | Momentum is often inconsistent for this stock due to sector volatility and reliance on reimbursement news. |
| Value investor | Weak fit | The stock often trades at valuations that require high future growth expectations to justify current pricing. |
| Dividend investor | Weak fit | The company does not pay a dividend and is not expected to initiate one in the near term. |
| Low-risk investor | Weak fit | High volatility and regulatory risks make this unsuitable for a low-risk investment profile. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on clinical trial results and reimbursement updates. |
| Valuation risk | Medium / high | The market prices in significant future growth, leaving little room for error in meeting quarterly targets. |
| Competition risk (Diagnostic testing) | High | Direct competition from firms like Natera threatens market share in the non-invasive testing segment. |
| Business quality | Medium | The company has a strong niche presence but carries the burden of ongoing integration and compliance requirements. |
| Dividend income | Low / none | Investors should not look to this stock for income generation. |
| Execution risk | Medium | Success depends on the company's ability to maintain high testing volumes and defend its reimbursement status. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 82.86% | Avg. Invested days 46 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/17/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.77B USD | Price to earnings Ratio 25.26 | 1Y Target Price 54.14 |
Price to earnings Ratio 25.26 | 1Y Target Price 54.14 | ||
Volume (30-day avg) 1.0M shares | Beta 2.43 | 52 Weeks Range 13.95 - 55.16 | Updated Date 09/17/2026 |
52 Weeks Range 13.95 - 55.16 | Updated Date 09/17/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.12 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostic Testing Services | Revenue from AlloSure, AlloMap, and other lab-based blood tests for transplant patients. | Most revenue comes from performing and billing for specialized medical tests ordered by transplant physicians. |
| Digital Health Solutions | Software platforms provided to transplant centers for patient and data management. | This segment provides recurring revenue via subscriptions for software that helps hospitals manage transplant workflows. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 25.26 | Forward PE 151.52 | Enterprise Value 2.42B | Price to Sales(TTM) 6.05 |
Enterprise Value 2.42B | Price to Sales(TTM) 6.05 | ||
Enterprise Value to Revenue 5.17 | Enterprise Value to EBITDA 152.2 | Shares Outstanding 51.73M | Shares Floating 49.47M |
Shares Outstanding 51.73M | Shares Floating 49.47M | ||
Percent Insiders 3.16 | Percent Institutions 103.3 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About CareDx Inc
Exchange NASDAQ | Headquarters Brisbane, CA, United States | ||
IPO Launch date 2014-07-17 | President, CEO & Director Mr. John Walter Hanna Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 761 | Website https://caredx.com |
Full time employees 761 | Website https://caredx.com | ||
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.